Abivax SA (ABVX) Stock Forecast
ABVX analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.67 / 5 from 12 analysts
- Price target
- $163.58 average of analyst targets
- Upside to target
- +85.6% from the latest close
- Next earnings
- —
- 52-week range
- $72.50 – $145.31
ABVX analyst ratings
12 analystsNumber of analysts at each rating.
ABVX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
ABVX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.86 | −$1.11 | −$0.61 | −$2.47 | +65.2% | 4 |
| Current fiscal year (2026) | −$4.19 | −$4.67 | −$3.89 | −$5.59 | +25.0% | 7 |
| Next fiscal year (2027) | −$3.85 | −$4.91 | −$2.58 | −$4.19 | +8.1% | 7 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
ABVX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $676,440 | $0 | $1.4M | −66.9% | 6 |
| Current fiscal year (2026) | $4.0M | $0 | $8.0M | −13.0% | 14 |
| Next fiscal year (2027) | $71.9M | $0 | $374.7M | +1,695.5% | 15 |
ABVX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
ABVX revenue: reported and forecast
ABVX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.69 | −$0.67 | −$0.76 | −$0.90 | −$0.86 | +24.2% | 0 up · 3 down |
| Current fiscal year (2026) | −$3.65 | −$3.59 | −$3.58 | −$4.24 | −$4.19 | +15.1% | 0 up · 6 down |
| Next fiscal year (2027) | −$3.27 | −$3.15 | −$3.34 | −$3.88 | −$3.85 | +18.0% | 2 up · 4 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
ABVX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; ABVX beat in 6 of 12.
What analysts expect from ABVX
12 analysts cover Abivax SA; their consensus rating is strong buy (4.67 on a 1–5 scale, where 5 is a strong buy). The average price target is $163.58, 85.6% above the latest close of $88.13. Analysts expect earnings of −$4.19 per share for 2026, +25.0% from a year earlier. For 2027 the average estimate is −$3.85 per share on revenue of $71.9 million. Abivax SA beat the EPS estimate in 6 of the last 12 quarters.
Related: ABVX income statement, ABVX key metrics, ABVX chart. See the ABVX stock overview for the latest quote and news.
ABVX forecast FAQ
What is Abivax SA's price target?
The average analyst price target for Abivax SA is $163.58, 85.6% above the latest close of $88.13.
Is Abivax SA a buy, hold or sell?
Of 12 analysts covering Abivax SA, 8 rate it a strong buy, 4 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Abivax SA's EPS forecast?
Analysts forecast −$4.19 per share for 2026 (range −$4.67 to −$3.89); for 2027 the estimate is −$3.85.
What is Abivax SA's revenue forecast?
The average revenue estimate for 2026 is $4.0 million, growth of −13.0%; for 2027 it is $71.9 million.
Does Abivax SA usually beat earnings estimates?
Abivax SA reported EPS at or above the analyst estimate in 6 of the last 12 quarters.